Evidence is scarce regarding the treatment of status epilepticus (SE). Only a few large randomized controlled trials have been published. Therefore, we set up a multicenter registry to prospectively document treatment practice in several different large hospitals in German-speaking countries. Over a period of more than 4 years, we were able to document 1179 episodes of 1049 patients who were treated for SE in 1 of the 8 participating centers in Germany, Austria, and Switzerland. Median age was 70 years. The most frequent etiology was remote (32%), followed by acute (31%), or a mixture of acute and remote factors (10%). Semiology was generalized convulsive in 44%, focal motor in 27%, and nonconvulsive in 30%. Only a few patients did not have relevant comorbidities. Median latency between SE onset and first treatment was 1 hour (median). Three hundred ninetythree (32%) of the patients were treated within 30 minutes after onset. The first treatment step consisted of benzodiazepines in more than 80%, and in levetiracetam in 15%. Five hundred eleven patients (49%) were refractory (defined as ongoing SE after application of benzodiazepine and 1 intravenous anticonvulsant).
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| INTRODUCTION
Evidence regarding the treatment of status epilepticus (SE) is scarce. There are only a few large randomized controlled trials that fulfill the criteria of Class 1 evidence. These trials focus on the first treatment step, [1] [2] [3] [4] and 3 of these trials exclusively investigate the effect of prehospital treatment. Several important inherent obstacles, such as the definition of equipoise, the problems of blinding, or of obtaining informed consent, have hitherto precluded the setup of a large trial focusing on established or refractory SE in Europe. In the United States, the Established Status Epilepticus Treatment Trial (ESETT) has been funded by the National Institutes of Health, but first results will not be published before 2018. Therefore, an informal working group of experts in status epilepticus of Germanspeaking countries has developed a prospective registry for patients treated for SE with the acronym SENSE (Sustained effort network for treatment of status epilepticus).
| METHODS
The methods and design of this registry have been published elsewhere. 5 In brief, 8 high-volume centers with expertise in treatment of SE participated and recruited patients: (1) Germany: Epilepsy Center Hessen/University of Marburg (Rosenow), University Hospital Kiel (Lang), Klinikum Osnabrück (Kellinghaus), Krankenhaus Barmherzige Brüder, Regensburg (Tilz), (2) Austria: Christian-Doppler-Klinik Universitätsklinikum der Paracelsus Medizinischen Universität Salzburg, (Trinka), University Hospital, Innsbruck (Unterberger); and (3) Switzerland: University Hospital Basel (Rüegg), University Hospital Lausanne (Rossetti) . SE was operationally defined as seizure duration of 5 minutes or longer, or consecutive seizures without returning to baseline >5 minutes, or comatose patients who fulfilled the EEG criteria for nonconvulsive SE as defined in Beniczky et al 6 .
We excluded patients with status-like phenomena owing to hypoxic brain injury, and patients under the age of 16 years.
We documented demographic variables, health-related variables at the time of SE onset, SE-related variables, treatment-related variables, and outcome-related variables. We used the modified Rankin scale 7, 8 for global assessment of health before SE onset and at hospital discharge, and the Status Epilepticus Severity Score (STESS). 9 Prehospital treatment was included in the assessments. Protocols of the participating institutions demand detailed documentation of all treatment steps regardless of time and location, and emergency services in those areas also document out-of-hospital application of drugs in detail. Thus, the data can be considered reliable.
Statistical calculations were performed with SPSS Version 24 (Chicago, IL, USA). Ranked variables were described using mean and standard deviation, and median/ quartiles when normal distribution could not be assumed. For univariate analysis of categorical data, chi-square test and Fisher's exact test (2 × 2 tables) were used. Intervalscaled or ordinal-scaled data were analyzed with the Mann-Whitney U test (comparison of 2 groups), or the Kruskal-Wallis test (comparison of 3 or more groups).
| RESULTS
Between January 2011 and June 2015, 1049 patients with 1179 episodes were enrolled in SENSE. We analyzed only the first episode of each patient.
Median age was 70 years and 514 patients (49%) were women. Other sociodemographic data, semiology, and comorbidities are summarized in Table 1 ; etiologies are summarized in Table 2 .
SE treatment started within 30 minutes after SE onset in 334 patients (32%), and in 297 patients (28%) between 30 minutes and 2 hours. Eighty-five patients (8%) received first treatment more than 24 hours after SE onset. In 138 patients (13%), time from SE onset to treatment onset could
Key Points
• In the SENSE registry, more than 1000 cases of status epilepticus treatment could be documented prospectively • In clinical practice, the first steps of SE treatment frequently consist of separate and low-dose applications of intravenous drugs • Despite frequent deviation from guideline policy, SE ceased during hospital stay in more than 90% of the cases not be determined with sufficient validity. More than a third of the patients were treated in prehospital settings before hospital admission. Ninety-nine of these patients received 2 drugs in the prehospital setting; 45 patients received 3 or more drugs. We observed that, in a relevant number of patients, more than 1 benzodiazepine was given within a brief period of time. Therefore, for the definition of status phase (established SE, refractory SE), we considered all different benzodiazepines administered as a first step before application of the first intravenous anticonvulsant as 1 step. The first 2 treatment steps are summarized in Table 3 .
The third treatment step was applied in 495 patients after a median latency of 135 minutes. The most frequently used substance was valproate (118 patients) followed by lacosamide (117 patients) and levetiracetam (59 patients). In 200 patients (40%), SE ceased after the third treatment step.
The fourth treatment step was applied in 285 patients and was successful in 105 patients (37%). Similar success rates were found for the subsequent treatment step. The highest number of treatment steps was 13 (1 patient).
Two hundred thirty-one patients (22%) were intubated during the treatment of the SE. In 136 patients (13%), intubation was performed solely for airway protection. In 84 patients (8%), intentional coma was induced for SE therapy. Fifty-four patients could not be treated successfully within a >24-hour period of intentional coma and were, thus, considered as super-refractory. In all these patients, SE could be ultimately stopped. However, 10 of these patients died during the hospital stay.
Ten substances were used in more than 50 patients ( Table 4 ). The numbers, bolus doses (if applicable), and the success rates (defined as the substance being the last drug administered before cessation of SE) can be found in Table 1 .
In 241 patients, a total of 370 adverse events were documented by the investigators; 64 of them were considered as serious. 
| DISCUSSION
The data of the SENSE registry show that, in the vast majority of the patients, SE (regardless of semiology and etiology) can be stopped eventually during the hospital stay. However, the success rate of the first and second treatment steps-regardless of the substance used-is much lower than in the large randomized controlled studies. This may be due to a relevant number of patients who received several substances within a very short time, thus shifting the point of success to a later phase of treatment. In addition, recruitment of the patient was in the in-patient setting.
Patients with successful treatment out-of-hospital may not have been admitted to the emergency room and, therefore, not included into this database. This may at least partially explain the low success rates. In addition, the bolus dose is lower than recommended in most cases and, in a relevant number of patients, benzodiazepines were not used as firstline agents. Whether this has any influence on refractoriness and/or outcome remains to be analyzed. This database has several limitations. First, contributions of different centers in terms of patient numbers were quite divergent. This decreases the homogeneity of the cohort and generalizability of the findings. In addition, there was no independent monitoring or comparison between source data and database entry. It is very likely that this has resulted in underreporting and other types of reporting bias. In addition, treatment was neither randomized nor controlled. Therefore, correlations between treatment data and outcome data have to be interpreted with caution.
However, our database documents treatment practice "as is" in centers with special expertise in treatment of SE. Its standardized documentation of important variables of more than 1000 patients will help to detect differences between the world of guidelines and recommendation and real life, and may, thus, improve patient care. Moreover, the database may be an important tool for generating hypotheses regarding course and treatment of SE and will help to design conclusive controlled trials.
| CONCLUSIONS
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